Protective Immunity to Human Cholera in Bangladesh

This study has been completed.
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00349999
First received: July 6, 2006
Last updated: September 5, 2013
Last verified: October 2009
  Purpose

The purpose of this study is to better understand how the body fights and protects against cholera. Two hundered fifty people presenting to the International Centre for Diarrhoeal Diseases Research, Bangladesh, admitted with acute cholera, 50 of whom (healthy, nonpregnant, 18-45 year olds) will be enrolled in this substudy of mucosal immunity involving duodenal biopsy. The remainder of the study is observational, involving collection of stool, vomit, and blood samples only. The biopsy requires a flexible tube with a camera be inserted through the mouth into the stomach and intestine. During this procedure, small samples will be collected from the intestine. The study includes medical history, physical, blood testing, hospitalization and urine pregnancy testing. This study will last for 5 years and patients will participate for 3 years.


Condition
Cholera

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protective Immunity to Human Cholera in Bangladesh-EGD Substudy

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Serum antibody responses to V cholerae Lipopolysaccharide (LPS) and Cholera Toxin, B Subunit (CTB) (and other antigens as needed) on Days 2, 7, and 30 and at Months 3, 6, 9, 12, 18, 24, 30, and 36 following enrollment. [ Time Frame: Days 2, 7, and 30 and at Months 3, 6, 9, 12, 18, 24, 30, and 36 following enrollment. ] [ Designated as safety issue: No ]
  • Mucosal responses to V cholerae LPS and CTB (and other antigens as needed) on Days 2 and 30 (in 50 study participants) and at Month 6 (25 study participants) and Month 12 (25 study participants) following enrollment. [ Time Frame: Days 2 and 30 (in 50 participants) and at Month 6 (25 study participants) and Month 12 (25 study participants) following enrollment. ] [ Designated as safety issue: No ]
  • Memory B and T cell responses to V cholerae LPS and CTB (and other antigens as needed) on Days 2 and 30 and at Months 3, 6, 9, 12, 18, 24, 39, and 36 following enrollment. [ Time Frame: Days 2 and 30 and at Months 3, 6, 9, 12, 18, 24, 39, and 36 following enrollment.. ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Duodenal biopsy samples and blood.


Enrollment: 125
Study Start Date: June 2008
Study Completion Date: December 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
18 males and non pregnant females, ages 18-45, with acute cholera.

Detailed Description:

Diarrheal diseases are some of the most common causes of morbidity and mortality in the world today. Unfortunately, effective vaccines for most of the infectious causes of diarrhea are not yet available. Vibrio cholerae (V cholerae) is an important infectious cause of severe secretory diarrhea in humans. The purpose of this study is to assess the duration of immune responses in a group of 250 individuals, aged 2-60 years, presenting to the International Centre for Diarrheal Diseases Research, Bangladesh (ICDDR,B) hospital who are admitted with acute cholera. Fifty of these participants will be enrolled in a substudy of mucosal immunity involving duodenal biopsy. This protocol focuses exclusively on the subset of 50 study participants (healthy 18-45 year old non pregnant subjects) enrolled in the substudy of mucosal immunity involving duodenal biopsy. This study is linked to DMID protocol 06-0045. The remainder of the study is observational, involving collection of stool, vomit, and blood samples only (DMID protocol 06-0045). A duodenal biopsy will be performed on enrollment or the next day and at Day 30. Twenty five subjects will undergo a third duodenal biopsy after 6 months of follow-up and 25 subjects will undergo a third duodenal biopsy after 12 months follow-up. The objectives of this study are as follows: to measure immune responses directed against Vibrio cholerae antigens and evaluate the development of anti-V cholerae memory B cells in study participants with cholera; to assess the duration of the immune responses following an episode of cholera; and to correlate the duration of antigen-specific, antibody-secreting cells for various cholera antigens in duodenal tissue with measurements of the duration of immunity based on antibody responses in serum, as well as circulating antigen-specific memory B cells. This is a single site study with a 5 year duration requiring three years of patient participation.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

18 males and nonpregnant females, without comorbid conditions, ranging from 18 to 45 years of age, inclusive, who are admitted to the International Centre for Diarrhoeal Research, Bangladesh (ICDDR,B) with acute cholera.

Criteria

Inclusion Criteria:

For the esophagogastroduodenoscopy (EGD) substudy of 50 study participants

  • Admission to the International Centre for Diarrhoeal Diseases Research, Bangladesh (ICDDR,B) with acute cholera
  • Male or nonpregnant female [pregnancy will be excluded by urine human chorionic gonadotropin (HCG) testing]
  • Age 18 to 45 years, inclusive
  • Residence in Dhaka city
  • Provision of informed consent for enrollment in study
  • Expressed interest and availability to fulfill the study requirements

Exclusion Criteria:

For the esophagogastroduodenoscopy (EGD) substudy of 50 study participants

  • Participation in any other investigational drug, device or vaccine trial at present or within the past 30 days
  • Known allergy to midazolam or topical anesthetics
  • Presence of comorbid conditions, including:
  • heart disease
  • pulmonary disease
  • liver disease
  • kidney disease
  • bleeding disorder
  • neurologic disorder
  • an additional intestinal disorder
  • pregnancy
  • anemia (hemoglobin < 12 g/dl for males or < 11 g/dl for female)
  • hypotension (systolic blood pressure less than or equal to 85 mm Hg or diastolic blood pressure less than or equal to 55 mm Hg, measured in the supine position once just prior to procedure)
  • hypertension (systolic blood pressure greater than or equal to 150 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg, measured in the supine position once just prior to procedure)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00349999

Locations
Bangladesh
Dhaka Hospital - International Centre for Diarrhoeal Disease Research, Bangladesh
Dhaka, Bangladesh, 1000
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00349999     History of Changes
Other Study ID Numbers: 05-0103, 5U01AI058935-14
Study First Received: July 6, 2006
Last Updated: September 5, 2013
Health Authority: Bangladesh: International Centre for Diarrhoeal Disease Research
United States: Institutional Review Board
United States: Federal Government
Bangladesh: Ethical Review Committee

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Vibrio cholerae, Cholera, Bangladesh, esophagogastroduodenoscopy, sub-study

Additional relevant MeSH terms:
Cholera
Vibrio Infections
Gram-Negative Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on July 28, 2014